Patents Examined by Laura B Goddard
  • Gene expression markers of tumor resistance to HER2 inhibitor treatment
    Patent number: 10385405
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 20, 2019
    Assignee: Genentech, Inc.
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • Anti-HER2 antibodies and methods of use
    Patent number: 10377825
    Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Mary Mathieu, Mark Dennis
  • Compositions and methods for treating malignancies
    Patent number: 10365280
    Abstract: Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 30, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Ruben Carrasco, Di Zhu
  • Lung cancer biomarkers and uses thereof
    Patent number: 10359425
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: September 9, 2009
    Date of Patent: July 23, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Marty Stanton, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A. E. Stewart
  • Nanoparticle drug delivery systems
    Patent number: 10342846
    Abstract: The invention provides pharmaceutical compositions and method of using the compositions, wherein the compositions comprise liposomes or micelles that contain one or more targeting peptides and/or anticancer drugs. In various embodiments, the components of the liposomes can include a) a phospholipid and optionally a lipid that is not a phospholipid; b) a pegylated lipid; c) a peptide-ethylene glycol (EG)-lipid conjugate wherein the peptide is a targeting ligand, and d) one or more drug-conjugated lipid, encapsulated drugs, or a combination thereof. The peptide-EG-lipid conjugate can be, for example, a compound of Formula (I) or Formula (II). The ethylene glycol (EG) segments of the peptide-EG-lipid conjugate can be, for example, EG6 to about EG36; and the EG segment can be conjugated to one or more lysine moieties.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: July 9, 2019
    Assignee: University of Notre Dame du Lac
    Inventors: Zihni Basar Bilgicer, Jonathan Ashley, Tanyel Kiziltepe Bilgicer, Jared Stefanick, Nathan J. Alves
  • Chimeric proteins and methods of immunotherapy
    Patent number: 10336807
    Abstract: The present disclosure provides systems for immune cell regulation and methods of immunotherapy. Systems of the present disclosure for immune cell regulation comprise a chimeric receptor polypeptide, a chimeric adaptor polypeptide, a gene modulating polypeptide (GMP), and a cleavage moiety.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 2, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Lei S. Qi, Bing C Wang
  • Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
    Patent number: 10338077
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering a treatment compound to a subject having cancer; obtaining a sample from the subject; determining the ratio of a first biomarker level to a second biomarker level in the sample from the subject, wherein at least one of the biomarkers is a CRBN-associated protein; and diagnosing the subject as being likely to be responsive to the treatment compound if the ratio of the biomarker levels in the sample of the subject changes as compared to a reference ratio of the biomarker levels.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: July 2, 2019
    Assignee: CELGENE CORPORATION
    Inventors: Hidekatsu Iha, Emi Ikebe
  • Anti-TIGIT antibodies
    Patent number: 10329349
    Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 25, 2019
    Assignee: iTeos Therapeutics SA
    Inventors: Anthony Cooper, Christophe Queva, Sofie Denies, Catherine Hoofd, Julia Cuende, Gregory Driessens, Florence Lambolez
  • Compositions and methods for treating multiple myeloma
    Patent number: 10302644
    Abstract: The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: May 28, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Teru Hideshima, Kenneth C. Anderson, Francesca Cottini
  • Antibodies against human CSF-1R and uses thereof
    Patent number: 10287358
    Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: May 14, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Nikolaos Dimoudis, Georg Fertig, Alexander Fidler, Guy Georges, Klaus Kaluza, Martin Lanzendoerfer, Carola Ries, Stefan Seeber, Marlene Thomas
  • Binding molecules specific for CD73 and uses thereof
    Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Treatment of cancer with anti-lap monoclonal antibodies
    Patent number: 10287347
    Abstract: Described herein are compositions and methods relating to LAP-binding agents, including, for example, anti-LAP antibodies, and to their use in methods of treatment of cancer. LAP-binding agents affected both systemic and intra-tumor immunity and were shown effective to treat a broad spectrum of cancer types.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: May 14, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Howard L. Weiner, Galina Gabriely, Andre Pires Da Cunha, Takatoku Oida
  • Humanized anti-CD134 (OX40) antibodies and uses thereof
    Patent number: 10273307
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 30, 2019
    Assignees: Biocerox Products B.V., Janssen Pharmaceuticals, Inc.
    Inventors: Petrus Johannes Simons, Louis Boon, Jinquan Luo, Randall Brezski, Monica Goldberg
  • Differential cerebrospinal fluid reactivity to PFDN5-alpha for detection of B-cell acute lymphoblastic leukemia
    Patent number: 10261086
    Abstract: A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-? from the patient, detecting reactivity of CSF against the PFDN5-?, comparing reactivity profile of CSF against the PFDN5-? at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: April 16, 2019
    Assignee: AMRITA VISHWA VIDYAPEETHAM
    Inventors: Krishna Kumar N. Menon, Tessy Xavier, Adhwyth Haridasan
  • Anti-FAP antibodies and methods of use
    Patent number: 10253110
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 9, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Method of modulating the activity of functional immune molecules
    Patent number: 10233247
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: March 19, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa
  • Antigen binding proteins
    Patent number: 10221234
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
    Patent number: 10221461
    Abstract: Disclosed are methods for determining the immunological status of the adaptive immune system of a subject by identifying and quantifying rearranged DNA (and/or subsequently transcribed RNA) sequences encoding T cell receptor (TCR) and/or immunoglobulin (IG) polypeptides, in a lymphoid DNA-containing sample from the subject TCR and/or IG sequence diversity and sequence distribution permit immunocompetence and immune repertoire assessment and reflect the degree of T cell or B cell clonality and clerical expansion in the sample. Methods for stratifying patient populations on the basis of immunocompetence including likelihood of responding to immunotherapy are also described.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 5, 2019
    Assignees: ADAPTIVE BIOTECHNOLOGIES CORP., MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Harlan S. Robins, Julie Rubinstein, Ryan Emerson, Jianda Yuan
  • Pan-HER antibody composition
    Patent number: 10221246
    Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 5, 2019
    Assignee: Symphogen A/S
    Inventors: Mikkel Wandahl Pedersen, Ida K. Christensen, Johan Lantto, Helle Jacobsen, Michael Kragh
  • Solubility optimization of immunobinders
    Patent number: 10221237
    Abstract: The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 5, 2019
    Assignee: ESBATech, an Alcon Biomedical Research Unit LLC
    Inventors: Leonardo Borras, David Urech